Reuters logo
Trevena's painkiller succeeds in two late-stage studies
February 21, 2017 / 12:25 PM / 7 months ago

Trevena's painkiller succeeds in two late-stage studies

Feb 21 (Reuters) - Trevena Inc said on Tuesday that its lead experimental drug oliceridine outperformed a placebo in two late-stage studies in patients suffering from acute pain.

The intravenous formulation was being tested in patients with moderate-to-severe acute pain following bunionectomy and abdominoplasty. (Reporting by Natalie Grover in Bengaluru; Editing by Shounak Dasgupta)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below